🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525748-14-00
Authorised Phase I

A clinical trial of MK-1824 in healthy participants (MK-1824-001)

2026-525748-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Merck Sharp & Dohme LLC
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
12/05/2026
Enrollment target
16
Sites
Belgium

Condition studied

Heart failure with preserved ejection fraction

Eligibility

Age group
18-64 years
Sex
Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525748-14-00 on CTIS ↗ ← All trials in the EU